BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grothey A, Blay J, Pavlakis N, Yoshino T, Bruix J. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treatment Reviews 2020;86:101993. [DOI: 10.1016/j.ctrv.2020.101993] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY, Cui Y, Niu P, Xu M, Liu MY. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness. World J Gastrointest Oncol 2022; 14(4): 920-934 [DOI: 10.4251/wjgo.v14.i4.920] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zottel A, Jovčevska I, Šamec N, Komel R. Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: A systematic review. Crit Rev Oncol Hematol 2021;160:103283. [PMID: 33667657 DOI: 10.1016/j.critrevonc.2021.103283] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Moehler M, Michel M, Stein A, Trojan J, Marquardt J, Tintelnot J, Waidmann O, Weinmann A, Woerns MA, Schroeder H, Maenz M, Foerster F. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer. Future Oncol 2021;17:3309-19. [PMID: 33993741 DOI: 10.2217/fon-2021-0278] [Reference Citation Analysis]
4 Seervai RNH, Cho WC, Chu EY, Marques-Piubelli ML, Ledesma DA, Richards K, Heberton MM, Nelson KC, Nagarajan P, Torres-Cabala CA, Prieto VG, Curry JL. Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy. J Cutan Pathol 2021. [PMID: 34622477 DOI: 10.1111/cup.14145] [Reference Citation Analysis]
5 Chang X, Ge X, Zhang Y, Xue X. The current management and biomarkers of immunotherapy in advanced gastric cancer. Medicine (Baltimore) 2022;101:e29304. [PMID: 35623069 DOI: 10.1097/MD.0000000000029304] [Reference Citation Analysis]
6 Reis NRP, Barbosa LER. Prognostic Factors and Management of Colorectal Gastrointestinal Stromal Tumors. Journal of Coloproctology. [DOI: 10.1055/s-0041-1740297] [Reference Citation Analysis]
7 Popescu V, Kanhaiya K, Năstac DI, Czeizler E, Petre I. Network controllability solutions for computational drug repurposing using genetic algorithms. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-05335-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Annadurai P, Gideon DA, Nirusimhan V, Ramachandran S, Dhandayuthapani K, Pugazhendhi A. Deciphering the pharmacological potentials of Aganosma cymosa (Roxb.) G. Don using in vitro and computational methods. Process Biochemistry 2022. [DOI: 10.1016/j.procbio.2022.01.024] [Reference Citation Analysis]
9 Ziletti A, Berns C, Treichel O, Weber T, Liang J, Kammerath S, Schwaerzler M, Virayah J, Ruau D, Ma X, Mattern A. Discovering Key Topics From Short, Real-World Medical Inquiries via Natural Language Processing. Front Comput Sci 2021;3:672867. [DOI: 10.3389/fcomp.2021.672867] [Reference Citation Analysis]
10 Lai E, Puzzoni M, Ziranu P, Cremolini C, Lonardi S, Banzi M, Mariani S, Liscia N, Cinieri S, Dettori M, Mencoboni M, Nappo F, Piacentini G, Labianca R, Zucchelli G, Boccaccino A, Conca V, Pusceddu V, Zaniboni A, Scartozzi M. Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study. Clinical Colorectal Cancer 2021. [DOI: 10.1016/j.clcc.2021.07.008] [Reference Citation Analysis]
11 Fukudo M, Asai K, Tani C, Miyamoto M, Ando K, Ueno N. Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes. Invest New Drugs 2021;39:1422-31. [PMID: 33830408 DOI: 10.1007/s10637-021-01115-4] [Reference Citation Analysis]
12 Zhao Z, Zheng Z, Huang J, Wang J, Peng T, Lin Y, Jian Z. Expression of ALG3 in Hepatocellular Carcinoma and Its Clinical Implication. Front Mol Biosci 2022;9:816102. [DOI: 10.3389/fmolb.2022.816102] [Reference Citation Analysis]
13 Gatto L, Franceschi E, Tosoni A, Di Nunno V, Maggio I, Tonon C, Lodi R, Agati R, Bartolini S, Brandes AA. Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review. Clin Case Rep 2021;9:e04604. [PMID: 34457284 DOI: 10.1002/ccr3.4604] [Reference Citation Analysis]
14 Conod A, Silvano M, Ruiz I Altaba A. On the origin of metastases: Induction of pro-metastatic states after impending cell death via ER stress, reprogramming, and a cytokine storm. Cell Rep 2022;38:110490. [PMID: 35263600 DOI: 10.1016/j.celrep.2022.110490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 He M, He Q, Cai X, Chen Z, Lao S, Deng H, Liu X, Zheng Y, Liu X, Liu J, Xie Z, Yao M, Liang W, He J. Role of lymphatic endothelial cells in the tumor microenvironment-a narrative review of recent advances. Transl Lung Cancer Res 2021;10:2252-77. [PMID: 34164274 DOI: 10.21037/tlcr-21-40] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zhang Q, Wang Z, Wu J, Zhou Z, Zhou R, Hu W. Bioequivalence and Pharmacokinetic Evaluation of Two Oral Formulations of Regorafenib: An Open-Label, Randomised, Single-Dose, Two-Period, Two-Way Crossover Clinical Trial in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Drug Des Devel Ther 2021;15:3277-88. [PMID: 34349503 DOI: 10.2147/DDDT.S323169] [Reference Citation Analysis]
17 Deshors P, Arnauduc F, Boëlle B, Cohen-jonathan Moyal E, Courtade-saïdi M, Evrard SM. Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells. Cancers 2022;14:1551. [DOI: 10.3390/cancers14061551] [Reference Citation Analysis]
18 Chen CH, Hsu FT, Chen WL, Chen JH. Induction of Apoptosis, Inhibition of MCL-1, and VEGF-A Expression Are Associated with the Anti-Cancer Efficacy of Magnolol Combined with Regorafenib in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2066. [PMID: 33922992 DOI: 10.3390/cancers13092066] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
19 Pathak S, Sonbol MB. Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction. J Hepatocell Carcinoma 2021;8:1147-58. [PMID: 34584898 DOI: 10.2147/JHC.S268314] [Reference Citation Analysis]
20 Lee MW, Miljanic M, Triplett T, Ramirez C, Aung KL, Eckhardt SG, Capasso A. Current methods in translational cancer research. Cancer Metastasis Rev 2021;40:7-30. [PMID: 32929562 DOI: 10.1007/s10555-020-09931-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Personeni N, Lleo A, Pressiani T, Colapietro F, Openshaw MR, Stavraka C, Pouptsis A, Pinato DJ, Rimassa L. Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers (Basel) 2020;12:E3370. [PMID: 33202975 DOI: 10.3390/cancers12113370] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
22 Zhang N, Zhang S, Wu W, Lu W, Jiang M, Zheng N, Huang J, Wang L, Liu H, Zheng M, Wang J. Regorafenib inhibits migration, invasion, and vasculogenic mimicry of hepatocellular carcinoma via targeting ID1-mediated EMT. Mol Carcinog 2021;60:151-63. [PMID: 33428809 DOI: 10.1002/mc.23279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Hansen TF, Qvortrup C, Pfeiffer P. Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. Cancers (Basel) 2021;13:1031. [PMID: 33804554 DOI: 10.3390/cancers13051031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Shapovalov V, Kopanitsa L, Pruteanu LL, Ladds G, Bailey DS. Transcriptomics-Based Phenotypic Screening Supports Drug Discovery in Human Glioblastoma Cells. Cancers (Basel) 2021;13:3780. [PMID: 34359681 DOI: 10.3390/cancers13153780] [Reference Citation Analysis]